Krystal Biotech, Inc.
NASDAQ:KRYSBiotechnology
+$18.29 today
- Market cap
- $9.34B
- Beta
- 0.53
- P/E (TTM)
- 44.5
- EPS (TTM)
- $7.68
Volume 0.35M
Average 0.29M
KRYS Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Krystal Biotech, Inc.NASDAQ: KRYS
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables rises 24.4% from a year ago
Net receivables stood at $138.66M at the end of Q2 FY2026, up 24.4% from a year earlier and up 9.2% from the prior quarter.
Context
- Net receivables amounted to 9.2% of total assets at the end of Q2 FY2026, down 0.5 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +24.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 127.43M USD
- Year-over-year change
- +21.7%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 127.43M | +21.7% |
| FY2024 | 2024-12-31 | 104.75M | +149.2% |
| FY2023 | 2023-12-31 | 42.04M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How KRYS compares with its peers on the latest reported figures
- KRYS's Jun 2026 net receivables of $138.66M is the highest of the 6 companies compared; the peer median is $6.71M.
- Its year-over-year change of +24.4% is the 3rd highest of 4, against a peer median of +243.7%.
- Net receivables amounts to 9.2% of total assets for KRYS, versus a peer median of 3.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $138.66M | +24.4% | — | 9.2% | |
| Mar 2026 | $17.96M | +243.7% | -14.3% | 7.3% | |
| Mar 2026 | $10.94M | -42.9% | -3.3% | 3.2% | |
| Mar 2026 | $6.71M | +314.9% | +229.3% | 3.4% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding KRYS) | $6.71M | +243.7% | -3.3% | 3.2% | |
Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 341.25M | 161.9M | 358.33M | 344.87M | 496.3M |
| Short-term Investments | 96.85M | 217.27M | 173.85M | 252.65M | 331.49M |
| Net Receivables | 0 | 0 | 42.04M | 104.75M | 127.43M |
| Inventory | 0 | 0 | 6.99M | 26.51M | 40.48M |
| Other Current Assets | 0 | 4.61M | 6.71M | 13.27M | 28.91M |
| Total Current Assets | 442.27M | 383.78M | 587.91M | 742.05M | 1.02B |
| Property, Plant & Equipment (Net) | 119.58M | 169.73M | 168.23M | 161.45M | 158.02M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 64.37M | 4.62M | 61.95M | 152.11M | 128.07M |
| Tax Assets | 0 | 0 | 0 | 0 | 22.82M |
| Other Non-current Assets | 74K | 324K | 263K | 231K | 287K |
| Total Non-current Assets | 184.03M | 174.67M | 230.45M | 313.79M | 309.19M |
| Total Assets | 626.3M | 558.45M | 818.36M | 1.06B | 1.33B |
| Account Payables | 8.4M | 3.98M | 1.85M | 4.99M | 3.24M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 83K | 43K | 2.28M | 4.29M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 87K | 267K | 16.75M | 2.4M | 3.58M |
| Total Current Liabilities | 25.74M | 28.85M | 33.09M | 102M | 102.94M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 1.42M | 3.72M |
| Total Non-current Liabilities | 6.98M | 7.37M | 6.62M | 7.46M | 11.29M |
| Total Liabilities | 32.72M | 36.22M | 39.71M | 109.46M | 114.23M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (140.78M) | (280.76M) | (269.83M) | (180.67M) | 24.16M |
| Accumulated OCI | (163K) | (728K) | 638K | (190K) | 1.14M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 593.58M | 522.23M | 778.64M | 946.38M | 1.22B |
| Total Debt | 8.02M | 8.93M | 8.09M | 7.26M | 9.34M |
| Net Debt | (333.22M) | (152.97M) | (350.23M) | (337.6M) | (486.97M) |
Krystal Biotech, Inc.
NASDAQ:KRYS
Intrinsic Alpha fair value
Locked
Current Price
$315.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.